Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Editor's Pick Challenging Clinical Case in Antimicrobial Resistance

Case Commentary: Imipenem/Cilastatin and Fosfomycin for Refractory Methicillin-Resistant Staphylococcus aureus Infection: a Novel Combination Therapy

George Sakoulas
George Sakoulas
aDivision of Host-Microbe Systems & Therapeutics, Center for Immunity, Infection & Inflammation, Collaborative to Halt Antimicrobial Resistant Microbes, University of California–San Diego School of Medicine, La Jolla, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.02039-20
  • Article
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Given that it is unlikely that randomized clinical trials will yield answers for treating the most challenging bacteremic infections caused by methicillin-resistant Staphylococcus aureus, clinicians, microbiologists, and pharmacists will have to cooperate to discover novel ways to select successful individualized antimicrobial therapy for these patients. An example of such a strategy was demonstrated in the identification and utilization of imipenem/cilastatin plus fosfomycin to treat a particularly recalcitrant MRSA bacteremia and spinal abscess.

The views expressed in this article do not necessarily reflect the views of the journal or of ASM.

INTRODUCTION

The case report of successfully using imipenem/cilastatin (IC) with fosfomycin to treat a case of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia with a deep-seated abscess with vertebral osteomyelitis translates laboratory microbiology into clinical use in a very complex case where there are not, and likely never will be, substantial clinical data (1). With the description of a remarkably long bacteremia of more than 1 month’s duration and a growing infection despite appropriate vancomycin or daptomycin, single antimicrobial therapy would generally be destined to fail, with emergence of resistance to these antibiotics being highly possible. Indeed, prolonged exposure to vancomycin can select for daptomycin-nonsusceptible MRSA (2), and persistence in vivo, with the selection pressure of cationic antimicrobial peptides even without the administration of any exogenous antibiotics, has also been shown to select for MRSA with reduced daptomycin susceptibility (3).

Treatment options in this case would have included some combination of antimicrobial therapy: daptomycin with a beta-lactam that would depend on regional availability (e.g., ceftaroline versus ceftobiprole, an antistaphylococcal beta-lactam, or cefazolin) (4–8); daptomycin plus fosfomycin (9–11), or perhaps daptomycin plus trimethoprim-sulfamethoxazole (12). Regarding consideration of vancomycin, the CAMERA-2 trial showed that a cephalosporin rather than a penicillin should be used to avoid the risk of acute kidney injury (13). Indeed, the take-home message of that study was not that combination therapy is not beneficial, but rather that not all combination therapies carry the same risk-benefit profile. Theoretically, telavancin might be considered given its dual mechanism of action at the membrane and cell wall, although the results of the halted clinical trial with this agent were never published (14). The IC-fosfomycin combination was chosen here based on Etest synergy testing, a more rapid method than conventional kill curves or checkerboards, which are too labor-intensive in clinical laboratory settings (1).

The use of antibiotics with mechanisms of action conferred at different steps in cell wall synthesis makes intuitive sense, and the use of Etest synergy testing to drive the decision of using these agents is novel and capable of being done by most clinical laboratories. This case encourages a more extensive evaluation of such methods in guiding decisions regarding antimicrobial therapy in challenging clinical cases of S. aureus bacteremia, where more than one antibiotic may be needed. The use of two beta-lactams demonstrating MRSA activity has been carried out in vitro, although no clinical evidence has been published (15, 16).

This case illustrates that in the most challenging cases of MRSA bacteremia, “outside-the-box” diagnostic and therapeutic steps must be taken to achieve clinical success. Such steps cannot be identified from treatment guidelines or other official documents that are increasingly relied upon to make system-wide antimicrobial stewardship decisions. Paradigms of monotherapy for all MRSA bacteremia appear to be in need of re-evaluation in order to avoid weeks-long trial-and-error therapy in order to achieve more rapid success. It remains to be determined if clinical trials offering level I guiding evidence can ever achieve the granularity to capture the clinical nuances required in the management of this case. It would be interesting to consider how this case would have played out if combination daptomycin plus a beta-lactam or imipenem plus fosfomycin had been used from the early stages. Might the patient have survived? One wonders if heart failure, which was presented as the cause of death, was the result of the progression of an endovascular infection such as endocarditis, given the increased risk of endocarditis in patients with vertebral spine infection (17). A future challenge for infectious disease physicians will be to identify these patients early in their course of their illness rather than relying on therapeutic failure to identify them, perhaps through emerging biomarker signatures (18).

  • Copyright © 2020 American Society for Microbiology.

All Rights Reserved.

REFERENCES

  1. 1.↵
    1. Nakamura I,
    2. Yamaguchi T,
    3. Aoki K,
    4. Miura Y,
    5. Sato S,
    6. Fujita H,
    7. Watanabe H
    . 2021. Imipenem plus fosfomycin as salvage therapy for vertebral osteomyelitis. Antimicrob Agents Chemother 65:e01746-20. doi:10.1128/AAC.01746-20.
    OpenUrlCrossRef
  2. 2.↵
    1. Sakoulas G,
    2. Alder J,
    3. Thauvin-Eliopoulos C,
    4. Moellering RC, Jr,
    5. Eliopoulos GM
    . 2006. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 50:1581–1585. doi:10.1128/AAC.50.4.1581-1585.2006.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Mishra NN,
    2. Yang SJ,
    3. Chen L,
    4. Muller C,
    5. Saleh-Mghir A,
    6. Kuhn S,
    7. Peschel A,
    8. Yeaman MR,
    9. Nast CC,
    10. Kreiswirth BN,
    11. Crémieux AC,
    12. Bayer AS
    . 2013. Emergence of daptomycin resistance in daptomycin-naïve rabbits with methicillin-resistant Staphylococcus aureus prosthetic joint infection is associated with resistance to host defense cationic peptides and mprF polymorphisms. PLoS One 8:e71151. doi:10.1371/journal.pone.0071151.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. McCreary EK,
    2. Kullar R,
    3. Geriak M,
    4. Zasowski EJ,
    5. Rizvi K,
    6. Schulz LT,
    7. Ouellette K,
    8. Vasina L,
    9. Haddad F,
    10. Rybak MJ,
    11. Zervos MJ,
    12. Sakoulas G,
    13. Rose WE
    . 2020. Multicenter cohort of patients with methicillin-resistant Staphylococcus aureus bacteremia receiving daptomycin plus ceftaroline compared with other MRSA treatments. Open Forum Infect Dis 7:ofz538. doi:10.1093/ofid/ofz538.
    OpenUrlCrossRef
  5. 5.↵
    1. Geriak M,
    2. Haddad F,
    3. Rizvi K,
    4. Rose W,
    5. Kullar R,
    6. LaPlante K,
    7. Yu M,
    8. Vasina L,
    9. Ouellette K,
    10. Zervos M,
    11. Nizet V,
    12. Sakoulas G
    . 2019. Clinical data on daptomycin plus ceftaroline versus standard of care monotherapy in the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 63:e02483-18. doi:10.1128/AAC.02483-18.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Barber KE,
    2. Werth BJ,
    3. Ireland CE,
    4. Stone NE,
    5. Nonejuie P,
    6. Sakoulas G,
    7. Pogliano J,
    8. Rybak MJ
    . 2014. Potent synergy of ceftobiprole plus daptomycin against multiple strains of Staphylococcus aureus with various resistance phenotypes. J Antimicrob Chemother 69:3006–3010. doi:10.1093/jac/dku236.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Trinh TD,
    2. Zasowski EJ,
    3. Lagnf AM,
    4. Bhatia S,
    5. Dhar S,
    6. Mynatt R,
    7. Pogue JM,
    8. Rybak MJ
    . 2017. Combination vancomycin/cefazolin (VAN/CFZ) for methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSI). Open Forum Infect Dis 4:S281–S. doi:10.1093/ofid/ofx163.631.
    OpenUrlCrossRef
  8. 8.↵
    1. Dhand A,
    2. Bayer AS,
    3. Pogliano J,
    4. Yang S-J,
    5. Bolaris M,
    6. Nizet V,
    7. Wang G,
    8. Sakoulas G
    . 2011. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis 53:158–163. doi:10.1093/cid/cir340.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Miró JM,
    2. Entenza JM,
    3. Del Río A,
    4. Velasco M,
    5. Castañeda X,
    6. Garcia de la Mària C,
    7. Giddey M,
    8. Armero Y,
    9. Pericàs JM,
    10. Cervera C,
    11. Mestres CA,
    12. Almela M,
    13. Falces C,
    14. Marco F,
    15. Moreillon P,
    16. Moreno A
    , Hospital Clinic Experimental Endocarditis Study Group. 2012. High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 56:4511–4515. doi:10.1128/AAC.06449-11.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Shaw E,
    2. Miró JM,
    3. Puig-Asensio M,
    4. Pigrau C,
    5. Barcenilla F,
    6. Murillas J,
    7. Garcia-Pardo G,
    8. Espejo E,
    9. Padilla B,
    10. Garcia-Reyne A,
    11. Pasquau J,
    12. Rodriguez-Baño J,
    13. López-Contreras J,
    14. Montero M,
    15. de la Calle C,
    16. Pintado V,
    17. Calbo E,
    18. Gasch O,
    19. Montejo M,
    20. Salavert M,
    21. Garcia-Pais MJ,
    22. Carratalà J,
    23. Pujol M
    , GEIH (Hospital Infection Study Group). 2015. Daptomycin plus fosfomycin versus daptomycin monotherapy in treating MRSA: protocol of a multicentre, randomised, phase III trial. BMJ Open 5:e006723. doi:10.1136/bmjopen-2014-006723.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Pujol M,
    2. Miro JM,
    3. Shah A, et al
    . 2018. Daptomycin plus fosfomycin versus daptomycin monotherapy for methicillin-resistant Staphylococcus aureus bacteremia. A multicenter, randomized, clinical trial, abstr LB3. In IDWeek 2018, San Francisco, CA, USA. Infectious Diseases Society of America, Arlington, VA.
  12. 12.↵
    1. Claeys KC,
    2. Smith JR,
    3. Casapao AM,
    4. Mynatt RP,
    5. Avery L,
    6. Shroff A,
    7. Yamamura D,
    8. Davis SL,
    9. Rybak MJ
    . 2015. Impact of the combination of daptomycin and trimethoprim-sulfamethoxazole on clinical outcomes in methicillin-resistant Staphylococcus aureus infections. Antimicrob Agents Chemother 59:1969–1976. doi:10.1128/AAC.04141-14.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Tong SYC,
    2. Lye DC,
    3. Yahav D,
    4. Sud A,
    5. Robinson JO,
    6. Nelson J,
    7. Archuleta S,
    8. Roberts MA,
    9. Cass A,
    10. Paterson DL,
    11. Foo H,
    12. Paul M,
    13. Guy SD,
    14. Tramontana AR,
    15. Walls GB,
    16. McBride S,
    17. Bak N,
    18. Ghosh N,
    19. Rogers BA,
    20. Ralph AP,
    21. Davies J,
    22. Ferguson PE,
    23. Dotel R,
    24. McKew GL,
    25. Gray TJ,
    26. Holmes NE,
    27. Smith S,
    28. Warner MS,
    29. Kalimuddin S,
    30. Young BE,
    31. Runnegar N,
    32. Andresen DN,
    33. Anagnostou NA,
    34. Johnson SA,
    35. Chatfield MD,
    36. Cheng AC,
    37. Fowler VG,
    38. Howden BP,
    39. Meagher N,
    40. Price DJ,
    41. van Hal SJ,
    42. O'Sullivan MVN,
    43. Davis JS
    , Australasian Society for Infectious Diseases Clinical Research Network. 2020. Effect of vancomycin or daptomycin with vs without an antistaphylococcal beta-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trial. JAMA 323:527–537. doi:10.1001/jama.2020.0103.
    OpenUrlCrossRef
  14. 14.↵
    1. Abdelhady W,
    2. Bayer AS,
    3. Gonzales R,
    4. Li L,
    5. Xiong YQ
    . 2017. Telavancin is active against experimental aortic valve endocarditis caused by daptomycin- and methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 61:e01877-16. doi:10.1128/AAC.01877-16.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Yoneda A,
    2. Thänert R,
    3. Burnham CD,
    4. Dantas G
    . 2020. In vitro activity of meropenem/piperacillin/tazobactam triple combination therapy against clinical isolates of Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus pseudintermedius and vancomycin-resistant Enterococcus spp. Int J Antimicrob Agents 55:105864. doi:10.1016/j.ijantimicag.2019.105864.
    OpenUrlCrossRef
  16. 16.↵
    1. Gonzales PR,
    2. Pesesky MW,
    3. Bouley R,
    4. Ballard A,
    5. Biddy BA,
    6. Suckow MA,
    7. Wolter WR,
    8. Schroeder VA,
    9. Burnham CA,
    10. Mobashery S,
    11. Chang M,
    12. Dantas G
    . 2015. Synergistic, collaterally sensitive β-lactam combinations suppress resistance in MRSA. Nat Chem Biol 11:855–861. doi:10.1038/nchembio.1911.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Murillo O,
    2. Grau I,
    3. Gomez-Junyent J,
    4. Cabrera C,
    5. Ribera A,
    6. Tubau F,
    7. Peña C,
    8. Ariza J,
    9. Pallares R
    . 2018. Endocarditis associated with vertebral osteomyelitis and septic arthritis of the axial skeleton. Infection 46:245–251. doi:10.1007/s15010-018-1121-9.
    OpenUrlCrossRef
  18. 18.↵
    1. Wozniak JM,
    2. Mills RH,
    3. Olson J,
    4. Caldera JR,
    5. Sepich-Poore GD,
    6. Carrillo-Terrazas M,
    7. Tsai CM,
    8. Vargas F,
    9. Knight R,
    10. Dorrestein PC,
    11. Liu GY,
    12. Nizet V,
    13. Sakoulas G,
    14. Rose W,
    15. Gonzalez DJ
    . 2020. Mortality risk profiling of Staphylococcus aureus bacteremia by multi-omic serum analysis reveals early predictive and pathogenic signatures. Cell 182:1311–1327.E14. doi:10.1016/j.cell.2020.07.040.
    OpenUrlCrossRef
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Case Commentary: Imipenem/Cilastatin and Fosfomycin for Refractory Methicillin-Resistant Staphylococcus aureus Infection: a Novel Combination Therapy
George Sakoulas
Antimicrobial Agents and Chemotherapy Dec 2020, 65 (1) e02039-20; DOI: 10.1128/AAC.02039-20

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Case Commentary: Imipenem/Cilastatin and Fosfomycin for Refractory Methicillin-Resistant Staphylococcus aureus Infection: a Novel Combination Therapy
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Case Commentary: Imipenem/Cilastatin and Fosfomycin for Refractory Methicillin-Resistant Staphylococcus aureus Infection: a Novel Combination Therapy
George Sakoulas
Antimicrobial Agents and Chemotherapy Dec 2020, 65 (1) e02039-20; DOI: 10.1128/AAC.02039-20
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • REFERENCES
  • Info & Metrics
  • PDF

KEYWORDS

MRSA
antimicrobial combinations
bacteremia

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596